Literature DB >> 30891896

Age-specific incidence rates and risk factors for respiratory syncytial virus-associated lower respiratory tract illness in cohort children under 5 years old in the Philippines.

Fumihiko Ueno1, Raita Tamaki1,2, Mayuko Saito1, Michiko Okamoto1, Mariko Saito-Obata1,3, Taro Kamigaki1, Akira Suzuki1, Edelwisa Segubre-Mercado4, Hananiah D Aloyon4, Veronica Tallo4, Socorro P Lupisan4, Hitoshi Oshitani1.   

Abstract

BACKGROUND: Respiratory syncytial virus (RSV) is one of the main viral causes of lower respiratory tract illness (LRTI), especially in young children. RSV vaccines, including maternal and infant vaccines, are under development; however, more epidemiological studies are needed to develop effective vaccination strategies.
OBJECTIVES: To estimate detailed age-specific incidence rates and severity of RSV-associated LRTI (RSV-LRTI) using data from a community-based prospective cohort study in the Philippines. PATIENTS/
METHODS: Cohort children who visited health facilities due to acute respiratory symptoms were identified, and nasopharyngeal swabs were collected to detect RSV. The severity of RSV-LRTI was assessed using the severity definition proposed by the World Health Organization. Risk factors for developing RSV-LRTI and contribution of SpO2 measurement were also evaluated.
RESULTS: A total of 395 RSV episodes which occurred in children aged 2-59 months were categorised as 183 RSV-LRTI, 72 as severe RSV-LRTI and 29 as very severe RSV-LRTI. Children aged 3-5 months had the highest incidence rate of RSV-LRTI, at 207.4 per 1000 child-years (95% CI: 149.0-279.5). Younger age group, place of living and low educational level of caregivers were associated with developing RSV-LRTI. Clinical manifestations had low levels of agreement with hypoxaemia as measured by pulse oximeter.
CONCLUSION: The highest burden of RSV was observed in young infants aged 3-5 months, whereas the burden was also high in those aged 12-20 months. Future vaccination strategies should consider the protection of older children, especially those aged one year, as well as young infants.
© 2019 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  cohort study; lower respiratory tract illness; pulse oximetry; respiratory syncytial virus

Mesh:

Substances:

Year:  2019        PMID: 30891896      PMCID: PMC6586181          DOI: 10.1111/irv.12639

Source DB:  PubMed          Journal:  Influenza Other Respir Viruses        ISSN: 1750-2640            Impact factor:   4.380


INTRODUCTION

Human respiratory syncytial virus (RSV), recently renamed as Human orthopneumovirus belonging to the Pneumoviridae family Orthopneumovirus genus,1 is one of the most important viral pathogens which causes lower respiratory tract illness (LRTI) including bronchiolitis and pneumonia, especially in infants and young children.2, 3 Respiratory syncytial virus is divided into two subgroups, A and B, based on antigenic and sequence variations. The predominant subgroup and proportion of each subgroup vary between epidemics.4 A recent global estimate showed that the incidence of RSV‐associated acute lower respiratory infection was 33.1 million, with 3.2 million hospital admissions and 59 600 in‐hospital deaths in children younger than 5 years old in 2015.5 Despite the burden of this disease, there are no commercially available vaccines and the monoclonal antibody is only a specific measure taken to prevent severe disease in high‐risk infants.6, 7 The incidence rate (IR) of RSV‐associated lower respiratory illness (RSVLRTI) is higher in the first 6 months of life compared with older age groups, and the illness is generally more severe in young infants.5, 8 For these reasons, it is believed that natural maternal immunity is not enough to prevent severe RSVLRTI in early infancy. Different strategies for vaccination, including maternal vaccination and infant vaccination, have been proposed to prevent severe infection.9, 10 However, effective implementation of these strategies depends on understanding the epidemiological patterns of severe infections, including age‐specific incidences. Respiratory syncytial virus infections are associated with various levels of respiratory illnesses, from cold‐like mild illness to very severe and even life‐threatening LRTI. To evaluate the disease burden and effectiveness of vaccines or other interventions, it is necessary to define the severity of RSV infection.11 To identify severe LRTI with hypoxaemia, percutaneous arterial oxygen saturation (SpO2) measurement by a pulse oximeter has been shown to be effective. Studies have reported that the recognition of hypoxaemia using a pulse oximeter improved the management of children with LRTI.12, 13 It was also shown that one of the most important indicators for severe RSVLRTI was an SpO2 level of less than 90%.14 Recently, the World Health Organization (WHO) expert group proposed that the measurement of SpO2 should be included in the severity definition for RSVLRTI.11 Several prospective cohort studies have been conducted in low‐ and middle‐income countries to define age‐specific IRs.15, 16, 17, 18, 19, 20, 21, 22 However, to date, few studies have reported the IR of RSVLRTI using standard definitions of severity. Hence, in this study, we analysed the data from a community‐based prospective cohort study of children younger than five years old to understand in detail the age‐specific incidence of RSVLRTI, using the definitions proposed by the WHO expert group.11 We examined possible risk factors for developing RSVLRTI and severe RSVLRTI and compared clinical manifestations between severe and non‐severe cases using data from a community‐based prospective cohort study in the Philippines. Further, we evaluated the level of concordance between the severity of the LRTI definitions and the classification based on the integrated management of childhood illness (IMCI).23

MATERIALS AND METHODS

Study design

In the previously described prospective cohort study,24, 25 a cohort of 4012 children younger than 5 years old was followed in two municipalities, Kawayan and Caibiran, on a main island of Biliran province in the Philippines, from March 2014 to June 2016. From this larger data set, we focused on respiratory tract illness (RTI) episodes identified at health facilities over a time window of exactly 2 years, between April 2014 and March 2016. Cohort children were identified by household visits. Demographic and socioeconomic information were collected using standard questionnaire forms by the study nurses, after obtaining written informed consent for participation from parents or guardians. Newborn infants were also recruited for the cohort. Duration of exclusive breastfeeding was checked with the caregivers through a retrospective interview. Study nurses recommended the caregivers to take their children to health facilities when children had difficulty breathing or chest indrawing. Those children who visited health facilities due to respiratory symptoms were evaluated by study nurses or a physician.24, 25 SpO2 was measured using pulse oximetry, the equipment for which (PalmSat® 2500A, Nonin Medical Inc., Minnesota, USA) was provided by the study. The study was approved by the Institutional Review Board of the Research Institute for Tropical Medicine and the Ethics Committee of Tohoku University Graduate School of Medicine.

Definition of RSV‐associated RTI

An RTI was defined as a respiratory episode with cough and/or difficult breathing. A new episode was identified if the onset of the new RTI episode was at least 7 days from the previous episode. An episode of RSV‐associated RTI (RSVRTI) was defined based on positive laboratory results for RSV. If there were two RSV‐positive samples within a month, the episode with the latter positive sample was considered as prolonged shedding, except if the RSV subgroups or the partial G gene sequences were different from each other.

Classification of RTI severity

We categorised RTIs into LRTI, severe LRTI and very severe LRTI based on the severity definitions proposed by the WHO expert group (Supporting Information Table S1).11, 26 Briefly, LRTI was defined as RTI with fast breathing (≥50 breaths/min in children aged 2‐11 months, ≥40 breaths/min in children aged 12‐59 months) or SpO2 < 95%; severe LRTI as LRTI with chest indrawing or SpO2 < 93% and very severe LRTI as LRTI with inability to feed, sleeping most of the time, difficult to wake or SpO2 < 90%. When RTI occurred in children aged 0‐1 month, the severity could not be defined based on the WHO definitions mentioned above.11, 26 Therefore, for this age group, we categorised RTI with ≥60 breaths/min or SpO2 < 95% as LRTI and RTI with chest indrawing or SpO2 < 93% as severe LRTI. We also classified RSV‐associated respiratory disease using Integrated Management of Child Illness (IMCI), both with and without the revision proposed in 2014.26 In this revision, children with pneumonia having chest indrawing without danger signs were classified as “pneumonia” (non‐severe disease). Hospitalisation of the children with severe respiratory disease was indicated by local treating physician.

Viral detection and defining RSV subgroups

Nasopharyngeal swabs were collected from RTI for RSV testing as described previously,27 including real‐time polymerase chain reaction (PCR) to screen for RSV,28, 29 conventional PCR for subgrouping and sequencing of the second variable region of the G gene (RSV‐A: 342 bp and RSV‐B: 330 bp).30, 31 Testing for RSV and other viruses, including rhinovirus, enterovirus, human metapneumovirus, human adenovirus, parainfluenza virus and influenza virus, was conducted using primers described in Supporting Information Table S2. Details of the procedure were described elsewhere.24 We did not exclude RSVRTI with other viruses from the analysis.

Statistical methods

Proportion of RSV subgroups by severe levels was compared using chi‐squared test. Agreement of severity classification between IMCI26 and the RSVLRTI severe case definition and agreement of SpO2 < 93% and having other clinical manifestations were measured using Cohen's kappa statistic. Age‐specific IRs were calculated for every three‐month age group, except for children aged <3 months. These IRs were calculated separately for 0‐1 month (as undefined RSVRTI) and 2 months old. The IRs of each age group were calculated as the sum of new episodes divided by the sum of the child‐years obtained for each age group. Poisson regression model was used to calculate 95% confidential interval (CI) of IRs. To evaluate the risk factors associated with developing RSVLRTI, we calculated hazard ratios (HRs) for total RSVLRTI (including RSVLRTI, severe and very severe RSVLRTI) and total severe RSVLRTI (severe LRTI and very severe LRTI) using the Cox proportional hazard model. Adjusted HRs (aHRs) were calculated by adjusting for age, sex and place of living (municipality) and other factors with P < 0.1 in the univariate analysis. Socioeconomic status was assessed using the Simple Poverty Scorecard® Poverty‐Assessment Tool Philippines.32 Extreme poverty was defined as a score <30 points. The hazard ratio for exclusive breastfeeding was calculated separately for children <6 months. The frequencies of the clinical manifestations were compared between children with severe (severe RSVLRTI and very severe RSVLRTI) and non‐severe (RSVRTI and RSVLRTI) cases, using logistic regression models. Adjusted odds ratios (aORs) were calculated by adjusting for age, sex and place of living. The cox proportional hazard regression models and the logistic regression models were performed using R version 3.4.4,33 with the survival package.34

RESULTS

Categorisation of RSV‐RTI episodes

The first RSV epidemic was observed from May 2014 to January 2015 with the RSV mainly being subgroup A, and the second epidemic was observed from October 2015 to January 2016, with the RSV mainly being subgroup B.27 This analysis included 3817 children, yielding 4629 child‐years of follow‐up from April 2014 to March 2016. During this period, 2916 RTI episodes were identified at the health facilities, among which, 408 were classified as RSVRTI (Figure 1).
Figure 1

Study participants and severity assessment for respiratory syncytial virus‐associated respiratory tract illness (RSV‐RTI) in Biliran cohort study, Philippines, from April 2014 to March 2016. LRTI, lower respiratory tract illness

Study participants and severity assessment for respiratory syncytial virus‐associated respiratory tract illness (RSVRTI) in Biliran cohort study, Philippines, from April 2014 to March 2016. LRTI, lower respiratory tract illness Among 408 RSVRTI episodes, 395 occurred in children aged 2 months or older, and 284 (71.9%) of those were placed into the RSVLRTI categories, including 183 RSVLRTI, 72 severe RSVLRTI and 29 very severe RSVLRTI (Figure 1). Six per cent of total RSVLRTI, 31% (31/101) of total severe RSV‐RLTI and 62% (18/29) of the very severe RSVLRTI episodes were identified by SpO2 only (Supporting Information Figure S1). Among total severe RSVLRTI (n = 101), 26 had SpO2 measured after starting oxygen treatment and at least 24% (24/101) had SpO2 < 90%, but only three were hospitalised. The proportion of RSV‐associated hospitalisation was 7.1% (28/395). Of these (n = 28), SpO2 data were available for 12 children and 25% (3/12) of those had SpO2 < 90%. There were 13 undefined RSVRTI episodes in children aged 0‐1 month, of which eight (61.5%) were hospitalised, all with chest indrawing, and three (23.1%) had SpO2 < 93% (Supporting Information Table S3). None of the 408 RSVRTI episodes was fatal.

Comparison between classification systems of severity

Among the 395 cases of children aged 2 months or older, using the RSVLRTI severity definition, the median age of children with RSVRTI was inversely associated with severity (Table 1). However, 71% (51/72) of the severe RSVLRTI and 51% (15/29) of the very severe RSVLRTI episodes occurred in children aged one year or older. The number of total RSVRTI in the municipality of Caibiran was twice that of Kawayan. In RSV‐associated hospitalisation, 96.4% (27/28) were classified as severe or very severe RSVLRTI. One hospitalised child had chest indrawing and inability to feed; however, this child did not have either fast breathing or SpO2 < 95%; therefore, this case was not classified as RSVLRTI.
Table 1

Characteristics and distributions of RSV‐RTI episodes based on the RSV‐LRTI severity definition in children aged 2 to 59 mo

Characteristics(1)(2)(3)(4)(2) + (3) + (4)(3) + (4)(1) + (2) + (3) + (4)
RSV‐RTI (n = 111)RSV‐LRTI (n = 183)Severe RSV‐LRTI (n = 72)Very severe RSV‐RLTI (n = 29)Total RSV‐LRTI (n = 284)Total severe RSV‐LRTI (n = 101)Total (n = 395)
Age in months, median [IQR]25 [11, 42]19 [11, 30]16 [10, 23]12 [6, 17]18 [10, 27]15 [9, 22]19 [10, 31]
Age in months, n (%)
2‐514 (13)30 (16)10 (14)6 (21)46 (16)16 (16)60 (15)
6‐1119 (17)17 (9)11 (15)8 (28)36 (13)19 (19)55 (14)
12‐2321 (19)70 (38)36 (50)12 (41)118 (42)48 (48)139 (35)
24‐3521 (19)32 (17)4 (6)3 (10)39 (14)7 (7)60 (15)
36‐5936 (32)34 (19)11 (15)0 (0)45 (16)11 (11)81 (20)
Sex, n (%)
Male51 (46)90 (49)41 (57)20 (69)151 (53)61 (60)202 (51)
Female60 (54)93 (51)31 (43)9 (31)133 (47)40 (40)193 (49)
Place of living (municipality), n (%)
Caibiran67 (60)132 (72)48 (67)16 (55)196 (69)64 (63)263 (66)
Kawayan44 (40)51 (28)24 (33)13 (45)88 (31)37 (37)134 (34)
Health facility, n (%)
Outpatient110 (99)183 (100)55 (76)19 (66)257 (90)74 (73)367 (93)
Hospitalisation1 (1)0 (0)17 (24)10 (34)27 (10)27 (27)28 (7)
IMCI classification, n (%)
Cough and cold109 (98)7 (4)4 (6)3 (10)14 (5)7 (7)123 (31)
Pneumonia0 (0)173 (94)15 (21)9 (31)197 (69)24 (24)197 (69)
Severe pneumonia or severe disease2 (2)3 (2)53 (74)17 (59)73 (26)70 (69)75 (26)
Revised IMCI classification, n (%)
Cough and cold109 (98)7 (4)4 (6)3 (10)14 (5)7 (7)123 (31)
Pneumonia0 (0)173 (94)68 (94)15 (52)256 (90)83 (82)256 (65)
Severe pneumonia or severe disease2 (2)3 (2)0 (0)11 (38)14 (5)11 (11)16 (4)
RSV subgroup
RSV‐A38 (34)42 (23)27 (38)8 (28)77 (27)35 (35)115 (29)
RSV‐B70 (63)131 (72)43 (60)17 (59)191 (67)60 (59)261 (66)
Undefined3 (3)10 (5)2 (3)4 (14)16 (6)6 (6)19 (5)
Co‐detected other viruses, n (%)
Human adenovirus1 (1)0 (0)2 (3)0 (0)2 (1)2 (2)3 (1)
Rhinovirus6 (5)13 (7)8 (11)3 (10)24 (8)11 (11)30 (7)
Enterovirus0 (0)1 (1)0 (0)0 (0)1 (0)0 (0)1 (0)
Human metapneumovirus0 (0)2 (1)0 (0)1 (3)3 (1)1 (1)3 (1)
Parainfluenza virus2 (2)2 (1)0 (0)0 (0)2 (1)0 (0)4 (1)
Influenza virus2 (2)3 (2)0 (0)0 (0)3 (1)0 (0)5 (1)

IMCI, integrated management of childhood illness; IQR, interquartile range; LRTI, lower respiratory tract illness; RSV, respiratory syncytial virus; RTI, respiratory tract illness.

Percentages are rounded off to integers. Total RSV‐LRTI consists of RSV‐LRTI, severe RSV‐LRTI and very severe RSV‐LRTI.

Characteristics and distributions of RSVRTI episodes based on the RSVLRTI severity definition in children aged 2 to 59 mo IMCI, integrated management of childhood illness; IQR, interquartile range; LRTI, lower respiratory tract illness; RSV, respiratory syncytial virus; RTI, respiratory tract illness. Percentages are rounded off to integers. Total RSVLRTI consists of RSVLRTI, severe RSVLRTI and very severe RSVLRTI. Comparing between RSVRTI severity definitions and IMCI classification, 98.2% (109/111) of RSVRTI episodes were classified as “cough or cold” by IMCI, 94.5% (173/183) of RSVLRTI episodes were classified as “pneumonia” and 58.6% (17/29) of very severe RSVLRTI cases as “severe pneumonia or very severe disease” (Table 1). The overall agreement between non‐severe (cough and cold/pneumonia; RSVRTI/RSVLRTI) and severe (severe pneumonia or severe disease; severe RSVLRTI/very severe RSVLRTI) classifications was 91.0%, and the kappa statistic was 0.74. When we applied the revised IMCI,26 which excluded having chest indrawing from the criteria of severe disease, none of the severe RSVLRTI episodes was classified as “severe pneumonia or severe disease” by IMCI (0/72) and 52% (15/29) of the very severe RSVLRTI cases were classified as “pneumonia” by IMCI. Within these 395 episodes, the subgroup of RSV was identified in 376 episodes. The proportion of severe or very severe episodes was higher in the subgroup A compared with the subgroup B without statistical significance (43.8% vs 29.9%, P = 0.06). Other viruses were also detected in 11.4% (46/395) of the episodes. Rhinovirus was the most frequently co‐detected virus (30/46) across all severity categories of RSVRTI (Table 1).

Age‐specific IRs of RSV‐LRTI

The overall IRs of total RSVLRTI and total severe RSVLRTI were 62.1 and 22.1 per 1000 child‐years in children aged 2‐59 months, respectively (Figure 2, Supporting Information Table S4). Incidence rates for children aged 2‐23 months were 124.0 and 51.5 per 1000 child‐years for total RSVLRTI and total severe RSVLRTI, respectively, and these IRs were significantly higher than those of children aged 24‐59 months (P < 0.001). Children aged 3‐5 months had the highest IRs for total RSVLRTI (207.4 per 1000 child‐years) and total severe RSVLRTI (74.5 per 1000 child‐years). The IRs of total RSVLRTI and total severe RSVLRTI declined in children aged 6‐8 months compared with children aged 3‐5 months (P = 0.001 and P = 0.125, respectively). Total RSVLRTI increased again in children aged 12‐14 months compared with children aged 9‐11 months without statistical significance (P = 0.07). After 20 months old, IRs declined with age. The same trends were seen when IRs were calculated by RSV subgroup, municipality or epidemics (Supporting Information Figure S2). When we considered RSVRTI with ≥60 breaths/min or SpO2 < 95% as LRTI and RSVRTI with chest indrawing or SpO2 < 93% as severe LRTI for children aged 0‐1 month, 8 out of 13 were severe RSVLRTI and the overall incidence rate of total RSVLRTI and that of total severe RSVLRTI were 63.1 and 23.5 per 1000 child‐years in children aged 0‐59 months, respectively.
Figure 2

Age‐specific incidence rates of RSV‐LRTI and distributions of followed up child‐years in children aged less than 5 y in Biliran cohort study from April 2014 to March 2016. LRTI, lower respiratory tract illness; RSV, respiratory syncytial virus. The proportion of severe episodes was calculated as proportion of the total severe RSV‐LRTI episodes among total RSV‐LRTI by every 1 y of age. Incidence rates were calculated for 2 mo of age and every 3 mo of ages from 3 to 59 mo of ages. Child‐years were calculated for every 3 mo of ages. The child‐years during RSV epidemic period is shown as dark grey in background, and light grey shows child‐years out of RSV epidemic period. The epidemic periods were defined as May 2014‐January 2015 and October 2015‐January 2016 during the study period of April 2014‐March 2016. Whiskers show 95% confidence interval of incidence rate for whole RSV‐LRTI in each age group

Age‐specific incidence rates of RSVLRTI and distributions of followed up child‐years in children aged less than 5 y in Biliran cohort study from April 2014 to March 2016. LRTI, lower respiratory tract illness; RSV, respiratory syncytial virus. The proportion of severe episodes was calculated as proportion of the total severe RSVLRTI episodes among total RSVLRTI by every 1 y of age. Incidence rates were calculated for 2 mo of age and every 3 mo of ages from 3 to 59 mo of ages. Child‐years were calculated for every 3 mo of ages. The child‐years during RSV epidemic period is shown as dark grey in background, and light grey shows child‐years out of RSV epidemic period. The epidemic periods were defined as May 2014‐January 2015 and October 2015‐January 2016 during the study period of April 2014‐March 2016. Whiskers show 95% confidence interval of incidence rate for whole RSVLRTI in each age group Fast breathing is one of the criteria for LRTI, and the cut‐off points differ by age (50 breaths/min in children aged 2‐11 months and 40 breaths/min in children aged 12‐59 months). To exclude the influence of age on the criteria for fast breathing, we calculated age‐specific IRs of RSVRTI with chest indrawing or SpO2 < 93% independently without using fast breathing. Incidence rates of RSVRTI episodes with chest indrawing and SpO2 < 93% were still high in those aged 12‐20 months, and particularly IR in 12‐14 months was higher than those in 6‐8 months for both chest indrawing and SpO2 < 93%. (Supporting Information Figure S3). The proportion of the total severe RSVLRTI episodes among total RSVLRTI was 42.7% (35/82) in the first year of life (2‐11 months) with the highest proportion in 9‐11 months (Figure 2). The proportion did not decline in the second year of life (40.7%, 48/118, P = 0.777) and decreased significantly only in the third year of life (17.9%, 7/39, P = 0.010).

Risk factor analysis for developing total RSV‐LRTI and total severe RSV‐LRTI

In the univariate analysis, younger age group, place of living and educational level of caregiver were significantly associated with developing both total RSVLRTI and total severe RSVLRTI (Table 2). Birth order and having other children aged <6 years in the same household were significantly associated with developing total severe RSVLRTI. After the adjustment, younger age group was still significantly associated with developing both total RSVLRTI (range of aHR: 1.7‐8.5) and total severe RSVLRTI (range of aHR: 7.5‐11.3) compared with the age group of 36‐59 months (Table 2). Living in the municipality of Caibiran was significantly associated with both total RSVLRTI (aHR: 2.5, 95% CI: 2.0‐3.2, P < 0.001) and total severe RSVLRTI (aHR: 1.9, 95% CI: 1.3‐2.8, P = 0.002). Low educational level of caregiver (≤10 years of education) was also a significant risk of developing total RSVLRTI (range of aHR: 1.5‐1.7). The aHR was lower in the group with exclusive breastfeeding than those with non‐exclusive breastfeeding, but this difference was not statistically significant (aHR: 0.2, 95% CI: 0.0‐1.2, P = 0.09). The other factors we examined were not significantly associated with developing RSVLRTI.
Table 2

Hazard ratios of risk factors for developing total RSV‐LRTI and total severe RSV‐LRTI in children aged 2‐59 mo

Risk factorsChild‐years (n = 4571)Total RSV‐LRTI (n = 284)Total severe RSV‐LRTI (n = 101)
nIRHR95% CIaHRa 95% CInIRHR95% CIaHRb 95% CI
Age in months
2‐524246190.18.3** 5.6‐12.48.5** 5.7‐12.71666.111.8** 5.5‐25.411.3** 5.2‐24.3
6‐114213685.53.7** 2.4‐5.83.8** 2.5‐5.91945.18.1** 3.9‐16.97.5** 3.6‐16.0
12‐23950118124.25.4** 3.9‐7.65.4** 3.8‐7.54850.59.1** 4.7‐17.48.3** 4.3‐16.1
24‐359863939.61.7** 1.1‐2.71.7** 1.1‐2.777.11.30.5‐3.31.20.5‐3.2
36‐5919724522.8 Ref Ref115.6 Ref Ref
Sex
Male239515062.6 Ref Ref6025.1 Ref Ref
Female217713461.61.00.8‐1.21.00.8‐1.34118.80.80.5‐1.10.80.5‐1.2
Place of living (municipality)
Caibiran216819690.42.5** 1.9‐3.22.5** 2.0‐3.26429.51.9** 1.3‐2.91.9** 1.3‐2.8
Kawayan24048836.6 Ref Ref3715.4 Ref Ref
Gestational age
≥36 wk414526864.7 Ref Ref9723.4 Ref Ref
<36 wk51358.80.90.3‐2.71.00.3‐3.0239.21.70.4‐6.51.80.4‐7.2
Unknown3751334.70.5** 0.3‐0.90.80.4‐1.525.30.2** 0.1‐0.90.40.1‐1.8
Birthweight (g)
≥ 2500305320466.8 Ref Ref7123.3 Ref Ref
<25005183057.90.90.6‐1.30.90.6‐1.41223.21.00.5‐1.81.10.6‐2.0
Unknown10005050.00.7* 0.5‐1.01.00.7‐1.41818.00.80.5‐1.31.30.8‐2.3
No. of family member (persons)
<7238513958.3 Ref Ref5121.4 Ref Ref
≥7218714566.31.10.9‐1.41.10.8‐1.35022.91.10.7‐1.60.80.5‐1.2
Having smoker in the same HH
No191612263.7 Ref Ref4624.0 Ref Ref
Yes265616261.01.00.8‐1.20.90.7‐1.15520.70.90.6‐1.30.70.5‐1.1
Birth order
1st14898959.8 Ref Ref2718.1 Ref Ref
2nd or 3rd182110557.71.00.7‐1.30.90.7‐1.23619.81.10.7‐1.81.10.6‐1.9
>3rd12629071.31.20.9‐1.61.00.7‐1.33830.11.7** 1.0‐2.71.50.9‐2.7
Socioeconomic status (points)
≥30230913960.2 Ref Ref4921.2 Ref Ref
<30226214564.11.10.8‐1.31.00.8‐1.35223.01.10.7‐1.60.90.6‐1.4
Educational level of caregiver (y)
≤612376855.01.30.8‐1.91.5** 1.0‐2.32520.21.40.7‐2.81.30.6‐2.8
7‐913209168.91.6** 1.1‐2.31.7** 1.2‐2.52518.91.30.7‐2.61.20.6‐2.4
1011728875.11.7** 1.2‐2.51.7** 1.2‐2.53933.32.3** 1.2‐4.42.1** 1.1‐4.1
≥118433743.9 Ref Ref1214.2 Ref Ref
Educational level of father (y)
≤613427958.90.90.6‐1.30.80.5‐1.13727.62.4* 1.0‐6.12.20.8‐5.7
7‐97484965.51.00.6‐1.50.80.5‐1.31621.41.90.7‐5.01.70.6‐4.8
105022549.80.80.4‐1.30.6* 0.4‐1.0815.91.40.5‐4.21.20.4‐3.6
≥114372966.4 Ref Ref511.4 Ref Ref
Unknown154310266.11.00.7‐1.50.90.6‐1.33522.72.00.8‐5.02.00.7‐5.3
House wall material
Light material14369968.9 Ref Ref3826.5 Ref Ref
Strong material313618559.00.90.7‐1.11.00.8‐1.36320.10.80.5‐1.10.90.6‐1.3
Kitchen location
Outside of household15839962.5 Ref Ref3824.0 Ref Ref
Inside of household298818561.91.00.8‐1.30.90.7‐1.26321.10.90.6‐1.30.80.6‐1.2
Fuel type for cooking
Electricity, LPG or kerosene3081755.2 Ref Ref516.2 Ref Ref
Solid fuel426326762.61.10.7‐1.91.00.6‐1.89622.51.40.6‐3.41.10.4‐2.9
Treatment of drinking water
Nothing207013665.7 Ref Ref4421.3 Ref Ref
Boil or bleach8095061.80.90.7‐1.31.10.8‐1.42227.21.30.8‐2.11.30.8‐2.2
Buying filtrated water16759858.50.90.7‐1.21.00.8‐1.33520.91.00.6‐1.51.00.7‐1.6
Others1700.0 NA NA00.0 NA NA
Owning private toilet
No198311558.0 Ref Ref4020.2 Ref Ref
Yes258916965.31.10.9‐1.41.3* 1.0‐1.66123.61.20.8‐1.71.40.9‐2.1
# of other children <6 yr in HH
None15758755.2 Ref Ref2817.8 Ref Ref
1184313372.21.3* 1.0‐1.71.10.9‐1.55328.81.6** 1.0‐2.51.30.8‐2.2
≥ 211546455.51.00.7‐1.40.80.6‐1.12017.31.00.6‐1.70.70.4‐1.3
# of other children 6‐14 yr in HH
None170210461.1 Ref Ref3520.6 Ref Ref
1‐2200611657.80.90.7‐1.21.00.8‐1.34220.91.00.7‐1.61.00.6‐1.6
≥ 38646474.11.20.9‐1.71.20.9‐1.62427.81.40.8‐2.21.10.6‐2.1
Breastfeeding statusc
Non‐exclusive breastfeeding479191.5 Ref Ref6127.7 Ref Ref
Exclusive breastfeeding708114.30.60.2‐1.60.60.2‐1.6228.60.2* 0.0‐1.10.2* 0.0‐1.2
Unknown12629230.21.20.6‐2.61.10.5‐2.3863.50.50.2‐1.50.50.2‐1.3

aHR, adjusted hazard ratio; HH, household; HR, hazard ratio; IR, incidence rate; LRTI, lower respiratory tract illness; RSV, respiratory syncytial virus.

Total RSV‐LRTI consists of RSV‐LRTI, severe RSV‐LRTI and very severe RSV‐LRTI. Total severe RSV‐LRTI consists of severe RSV‐LRTI and very severe RSV‐LRTI. Caregiver is the person that takes care of the child, knows best about the child and makes decisions for the best interest of the child. Solid fuel contains wood, charcoal, paper, etc

Adjusted for age group, sex, place of living, gestational age, birthweight, educational level of caregiver and number of other children <6 y in household.

Adjusted for age group, sex, place of living, gestational age, birth order, educational level of caregiver and father and number of other children <6 y in household.

Hazard ratio for breastfeeding status was adjusted for age group, sex, place of living and educational level of caregiver and calculated using subset data for 2‒6 y old.

P < 0.1.

P < 0.05.

Hazard ratios of risk factors for developing total RSVLRTI and total severe RSVLRTI in children aged 2‐59 mo aHR, adjusted hazard ratio; HH, household; HR, hazard ratio; IR, incidence rate; LRTI, lower respiratory tract illness; RSV, respiratory syncytial virus. Total RSVLRTI consists of RSVLRTI, severe RSVLRTI and very severe RSVLRTI. Total severe RSVLRTI consists of severe RSVLRTI and very severe RSVLRTI. Caregiver is the person that takes care of the child, knows best about the child and makes decisions for the best interest of the child. Solid fuel contains wood, charcoal, paper, etc Adjusted for age group, sex, place of living, gestational age, birthweight, educational level of caregiver and number of other children <6 y in household. Adjusted for age group, sex, place of living, gestational age, birth order, educational level of caregiver and father and number of other children <6 y in household. Hazard ratio for breastfeeding status was adjusted for age group, sex, place of living and educational level of caregiver and calculated using subset data for 2‒6 y old. P < 0.1. P < 0.05.

Clinical signs and symptoms associated with severe and very severe LRTI in RSV‐RTI

In the comparison of clinical signs and symptoms between severe (severe RSVLRTI and very severe RSVLRTI) and non‐severe (RSVRTI and RSVLRTI) cases, having decreased breath sounds (aOR: 8.6, 95% CI: 1.9‐60.4), wheezing (aOR: 3.1, 95% CI: 1.9‐5.2), rales (aOR: 6.2, 95% CI: 3.5‐11.9), alar flaring (aOR: 26.7, 95% CI: 11.1‐75.3), axillary temperature ≥38°C (aOR: 2.0, 95% CI: 1.2‐3.4) and tachycardia (aOR: 2.0, 95% CI: 1.2‐3.3) were all significantly associated with severe cases after adjusting for age group, gender and place of living (Table 3). Grunting, decreasing breath sound and alar flaring had high specificity of more than 97%. The positive predictive value for severe cases was high for alar flaring (85.7%), whereas the negative predictive value was high for wheezing (80.7%) and alar flaring (81.5%). Although co‐detection of rhinovirus was not significantly associated with severe cases (aOR: 1.4, 95% CI: 0.6‐3.1, P = 0.390), the specificity for severe cases was as high as 93.5%. Decreasing breath sounds, wheezing, rale, alar flaring and chest indrawing were significantly associated with SpO2 < 93% (P < 0.05), without high levels of agreement (kappa statistic: 0.1‐0.3) (Table 3).
Table 3

Adjusted odds ratios for comparison of clinical manifestations between severe and non‐severe RSV‐LRTI and agreement between clinical manifestation and SpO2 < 93%

Clinical manifestationTotalNon‐severe caseSevere caseaORa 95% CI P‐valueSensitivitySpecificityAgreement with SpO2 < 93%
RSV‐RTI and RSV‐LRTISevere and very severe RSV‐RTI
n = 395n = 294 (%)n = 101 (%)%κ
Illness history
Convulsion
No391290 (74.2)101 (25.8)      
Yes44 (100)0 (0.0)  
Pallor
No394293 (74.4)101 (25.6)      
Yes11 (100)0 (0.0)  
Physical examination
Grunting
No380287 (75.5)93 (24.5) Ref     
Yes157 (46.7)8 (53.3)2.91.0‐8.80.0527.9%97.6%84.20%0.1
Decreasing breath sound
No386292 (75.6)94 (24.4) Ref     
Yes92 (22.2)7 (77.8)8.61.9‐60.40.016.9%99.3%85.30%0.1
Wheezing sounds
No281227 (80.8)54 (19.2) Ref     
Yes11467 (58.8)47 (41.2)3.11.9‐5.2<0.00146.5%77.1%71.90%0.2
Rales
No174159 (91.4)15 (8.6) Ref     
Yes221135 (61.1)86 (38.9)6.23.5‐11.9<0.00185.1%53.9%54.60%0.1
Alar flaring
No353288 (81.6)65 (18.4) Ref     
Yes426 (14.3)36 (85.7)26.711.1‐75.3<0.00135.6%98.0%83.90%0.2
Chest indrawing
No325293 (90.2)32 (9.8)       
Yes701 (1.4)69 (98.6)790.6156.6‐14 558.7<0.00168.30%99.70%82.80%0.3
Central cyanosis
No395288 (81.6)65 (25.6)      
Yes06 (14.3)36  
Apnoea
No395294 (74.4)101 (25.6)      
Yes0   
Poor skin turgor
No395294 (74.4)101 (25.6)      
Yes0   
Vital signs
Axillary temperature
<38°C300232 (77.3)68 (22.7) Ref     
≥38°C9562 (65.3)33 (34.7)21.2‐3.40.00832.7%78.9%71.00%0.1
Tachycardia
No302233 (77.2)69 (22.8) Ref     
Yes9361 (65.6)32 (34.4)21.2‐3.30.0131.7%79.3%72.10%0.1
Co‐detected virus
Rhinovirus
No365275 (75.3)90 (24.7) Ref     
Yes3019 (63.3)11 (36.7)1.40.6‐3.10.3910.9%93.5%80.30

LRTI, lower respiratory tract illness; OR, odds ratio; RSV, respiratory syncytial virus; RTI, respiratory tract illness.

Non‐severe RSV‐RTI consists of RSV‐LRTI and RSV‐RTI. Tachycardia is defined by age: >160 pulse/min for younger than 12 mo, >150 pulses/min for 12‐35 mo and >140 pulse/min for 36‐59 mo.

Adjusted for age group, sex and municipality

Adjusted odds ratios for comparison of clinical manifestations between severe and non‐severe RSVLRTI and agreement between clinical manifestation and SpO2 < 93% LRTI, lower respiratory tract illness; OR, odds ratio; RSV, respiratory syncytial virus; RTI, respiratory tract illness. Non‐severe RSVRTI consists of RSVLRTI and RSVRTI. Tachycardia is defined by age: >160 pulse/min for younger than 12 mo, >150 pulses/min for 12‐35 mo and >140 pulse/min for 36‐59 mo. Adjusted for age group, sex and municipality

DISCUSSION

Using data from a prospective cohort study of rural communities in the Philippines, we examined the incidence rates and severity of RSVLRTI in detail. We estimated the overall IR of total RSVLRTI to be 62.1 per 1000 child‐years in children aged 2‐59 months. These rates are comparable to recent global estimates for IRs in low‐ to upper‐middle‐income countries, which are in the range of 41‐94 per 1000 child‐years in children aged 0‐59 months (from limited data with different methodologies).5 Other community‐based cohort studies conducted in low‐ and middle‐income countries have reported higher IRs for total RSVLRTI of up to 71‐94 per 1000 child‐years in Nigeria, Kenya and Indonesia.15, 18, 20 Such differences may be due to the fact that these studies conducted active case findings of children with acute respiratory symptoms, whereas we analysed children who visited health facilities, potentially underestimating IRs. We found that age‐specific IRs were significantly higher in children younger than 2 years old than in the older age group, and the same pattern was observed for total severe LRTI. Among those, the IRs of total RSVLRTI and total severe RSVLRTI were especially high in children aged 3‐5 months. Peak IRs found in previous similar studies were 3‐5 months in Nigeria, 0‐5 months in Kenya and 6‐8 months in Indonesia.15, 18, 20 In the Indonesian study, the IR was lower in children aged 3‐5 months than in those aged 6‐8 months, which may have been related to different factors such as the level of maternal antibodies35, 36 or breastfeeding practice,37 since young infants were likely to develop RSV‐associated bronchiolitis and pneumonia.38 Interestingly, we found that IRs dropped in children aged 6‐8 months and 9‐11 months, then increased again in children aged 12‐14, 15‐17 and 18‐20 months (Figure 2), in a pattern similar to previous studies.15, 18, 20 In hospital‐based studies, a majority of RSV‐associated severe infections are seen in infants aged <1 year, especially in young infants aged <6 months.19, 39 However, our study and other prospective cohort studies have identified similar bimodal peaks in IRs of total RSVLRTI, that is, young infants aged <6 months and children aged 12‐23 months. We suspected that the increased IRs in children aged 12‐20 months might be due to the change in the criteria for fast breathing at 12 months old. However, the age‐specific IRs of severe RSVLRTI defined by only chest indrawing or SpO2 < 93% showed similar patterns, suggesting a true increase in incidence in the second years of life. Age‐specific IRs might also be affected by the timing of RSV epidemics since observed child‐year for each age group did not cover whole epidemic periods. Therefore, we compared the proportion of epidemic period in total observed child‐years for each age group. We found not much difference in the proportions of epidemic periods between age groups. The age‐specific pattern of IRs for RSVLRTI has important implications for future intervention strategies including vaccination. While current vaccination strategies focus primarily on protecting young infants, if the IRs of RSVLRTI (especially the more severe cases) are also high in children 12‐23 months, vaccination strategies may need to consider including a booster dose before 12 months. In our study, 13 undefined RSVRTI episodes were identified in children aged <2 months due to unavailability of severity definitions.11, 26 Eight were hospitalised, and all of these had chest indrawing and three of them had SpO2 < 93%. Therefore, more than half of RSVRTI in children aged <2 months were considered to be severe. Incidence rates for those with chest drawing and SpO2 < 93% were highest in this age group, indicating the significant impact of RSVRTI in this age group. To reveal true burden and risk factors for this age group, further studies, particularly large‐scale birth cohort studies, should be conducted. We found that younger age of children (range of aHRs for total RSVLRTI and total severe RSVLRTI: 1.7‐8.5 and 7.5‐11.3, respectively), living in Caibiran (aHRs for total RSVLRTI: 2.4, 95% CI: 1.9‐3.1 and for total severe RSVLRTI: 1.9, 95% CI: 1.3‐2.8) and lower educational level of caregivers (range of aHRs for total RSVLRTI: 1.5‐1.7) were significant risk factors for the development of total RSVLRTI and total severe RSVLRTI (Table 2). Caibiran had a larger epidemic of RSV, and particularly RSV‐B, in 2015.27 Although the reasons for such differences are unknown, epidemiological patterns of RSV epidemics including their size can vary among different locations and also between epidemics even in the same location. It is therefore important to conduct longitudinal studies in multiple locations to assess the true impact of RSV in communities. Low educational level of caregiver has been often cited as a risk factor for developing severe RSV infections,40, 41 as we found here. Other commonly identified risk factors, such as prematurity (OR: 2.0), low birthweight (OR: 1.9), being male (OR: 1.2), having siblings (OR: 1.6), household crowding (OR: 1.9) and non‐exclusive breastfeeding (OR: 2.2), identified in a meta‐analysis,42 were not significant risk factors in the present study. Prematurity and low birthweight were significantly associated with acute lower respiratory infection in case‐control studies conducted in the hospital settings with a large number of children with severe RSVLRTI in high‐income countries.42 In our study, which mainly included cases in primary care, we did not reach the statistical significance probably due to the insufficient number of children with low birthweight, prematurity and severe RSVLRTI. In other low‐ and middle‐income countries, only unpublished data of one case‐control study and one cohort study for prematurity and one cohort study for low birthweight were conducted and none of these studies showed prematurity or low birthweight as a significant risk factor for severe RSVLRTI.42 Children whose gestational age or birthweight was not reported by their mothers (categorised as “unknown”) were less likely to develop RSVLRTI compared with the reference group. There may be a recall bias that mothers who could not recall were more likely to have had children with normal weight and gestational age. We included a relatively large number of children in our cohort study, but the number was still too small to assess all possible risk factors. Most other studies of risk factors have been conducted as case‐control studies, which are more suitable for evaluating risk factors that occur with low frequency, such as prematurity and low birthweight.42 In another prospective cohort study in Bohol, the Philippines, being male and having siblings were identified as significant risk factors,43 although there were some differences in the study designs. The Bohol study used RSV‐associated hospitalisation as an outcome and had twice as many participants as our study. On the other hand, a birth cohort study in Kilifi, Kenya, with fewer participants than ours,44 having 1‐2 siblings less than 6 years old living in the same household, was a statistically significant risk factor for developing total RSVLRTI. Thus, further studies are necessary to comprehensively evaluate various risk factors for developing severe RSV infections. As a previous study showed,45 clinical manifestations, such as wheezing, rale, alar flaring and chest indrawing, were significantly associated with SpO2 < 93% in our study. However, these clinical manifestations had low level of agreement with SpO2. Predicting hypoxaemia by clinical manifestation seemed difficult because no sole clinical sign had high sensitivity and specificity as described elsewhere.45, 46 The combination of the clinical manifestations in Usen et al’s study in Gambia had 70% of sensitivity and 79% of specificity.45 Moreover, 32% of severe and 62% of very severe cases were only defined by SpO2 level without meeting other clinical criteria of the WHO RSVLRTI case definition. Therefore, it should be emphasised that the diagnostic value of SpO2 measurement increased as the level of severity increased. Some studies have shown that hypoxaemia is more prevalent in children with RSVLRTI compared with LRTI with other aetiology.47, 48 In our study, 19% (19/101) of the total severe RSVLRTI had SpO2 < 90%. However, only 16% (3/19) of those were actually hospitalised. Taken together, testing for hypoxaemia is crucial for evaluation of children with RSV‐associated RTI to identify severe cases. Home care for children with LRI should be considered with SpO2 measurement. However, setting a cut‐off point for application of the oxygen therapy and providing the necessary equipment are important to support health workers’ decision. One limitation of our study was that we only included episodes observed in health facilities. Since health‐seeking behaviour can vary among age groups,49 we may have underestimated the IRs, particularly in older children who are less likely to visit health facilities than infants. Also, our study only included two sites from the same small island with two epidemics over two years, and thus, our results, including IRs, may not reflect the true burden. In addition, the study was not conducted as a birth cohort and most newborn infants were not recruited for the study immediately after birth. Therefore, observed child‐years in this age group were particularly small in infants aged less than 3 months.

CONCLUSION

Although young infants had the highest risk of developing severe and very severe RSVLRTI, there were also significant impacts on the second year of life. Future interventions, including vaccination, should consider children up to two years old as a population vulnerable to severe RSVLRTI. Integrated child care approaches should include the use of a pulse oximeter to evaluate the severity of LRTI, and adequate oxygen treatment should be given to severe LRTI with hypoxaemia. Click here for additional data file. Click here for additional data file. Click here for additional data file. Click here for additional data file. Click here for additional data file. Click here for additional data file. Click here for additional data file.
  45 in total

1.  ICTV Virus Taxonomy Profile: Pneumoviridae.

Authors:  Bert Rima; Peter Collins; Andrew Easton; Ron Fouchier; Gael Kurath; Robert A Lamb; Benhur Lee; Andrea Maisner; Paul Rota; Linfa Wang
Journal:  J Gen Virol       Date:  2017-10-31       Impact factor: 3.891

2.  Potential impact of maternal vaccination on life-threatening respiratory syncytial virus infection during infancy.

Authors:  Nienke M Scheltema; Xynthia M Kavelaars; Kentigern Thorburn; Marije P Hennus; Job B van Woensel; Cornelis K van der Ent; José A M Borghans; Louis J Bont; Julia Drylewicz
Journal:  Vaccine       Date:  2018-06-22       Impact factor: 3.641

3.  Viral etiology of pneumonia in a cohort of newborns till 24 months of age in Rural Mirzapur, Bangladesh.

Authors:  Khundkar Hasan; Pauline Jolly; Grace Marquis; Eliza Roy; Goutam Podder; Khorshed Alam; Fazlul Huq; Richard Sack
Journal:  Scand J Infect Dis       Date:  2006

4.  Molecular epidemiology of respiratory syncytial virus infections among children with acute respiratory symptoms in a community over three seasons.

Authors:  Mizuho Sato; Reiko Saito; Takatsugu Sakai; Yasuko Sano; Makoto Nishikawa; Asami Sasaki; Yugo Shobugawa; Fumitake Gejyo; Hiroshi Suzuki
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

5.  Respiratory syncytial virus (RSV) in infants hospitalized for acute lower respiratory tract disease: incidence and associated risks.

Authors:  Adriana Gut Lopes Riccetto; José Dirceu Ribeiro; Marcos Tadeu Nolasco da Silva; Renata Servan de Almeida; Clarice Weis Arns; Emílio Carlos Elias Baracat
Journal:  Braz J Infect Dis       Date:  2006-10       Impact factor: 1.949

6.  Respiratory syncytial virus infection and disease in infants and young children observed from birth in Kilifi District, Kenya.

Authors:  D James Nokes; Emelda A Okiro; Mwanajuma Ngama; Rachel Ochola; Lisa J White; Paul D Scott; Michael English; Patricia A Cane; Graham F Medley
Journal:  Clin Infect Dis       Date:  2008-01-01       Impact factor: 9.079

Review 7.  Risk factors for respiratory syncytial virus associated with acute lower respiratory infection in children under five years: Systematic review and meta-analysis.

Authors:  Ting Shi; Evelyn Balsells; Elizabeth Wastnedge; Rosalyn Singleton; Zeba A Rasmussen; Heather J Zar; Barbara A Rath; Shabir A Madhi; Stuart Campbell; Linda Cheyenne Vaccari; Lisa R Bulkow; Elizabeth D Thomas; Whitney Barnett; Christian Hoppe; Harry Campbell; Harish Nair
Journal:  J Glob Health       Date:  2015-12       Impact factor: 4.413

8.  Pulse oximetry for children with pneumonia treated as outpatients in rural Malawi.

Authors:  Eric D McCollum; Carina King; Rashid Deula; Beatiwel Zadutsa; Limangeni Mankhambo; Bejoy Nambiar; Charles Makwenda; Gibson Masache; Norman Lufesi; Charles Mwansambo; Anthony Costello; Tim Colbourn
Journal:  Bull World Health Organ       Date:  2016-10-11       Impact factor: 9.408

9.  Severity of Pneumonia in Under 5-Year-Old Children from Developing Countries: A Multicenter, Prospective, Observational Study.

Authors:  Thomas Bénet; Valentina Sanchez Picot; Shally Awasthi; Nitin Pandey; Ashish Bavdekar; Anand Kawade; Annick Robinson; Mala Rakoto-Andrianarivelo; Maryam Sylla; Souleymane Diallo; Graciela Russomando; Wilma Basualdo; Florence Komurian-Pradel; Hubert Endtz; Philippe Vanhems; Gláucia Paranhos-Baccalà
Journal:  Am J Trop Med Hyg       Date:  2017-07       Impact factor: 2.345

10.  Factors associated with increased risk of progression to respiratory syncytial virus-associated pneumonia in young Kenyan children.

Authors:  Emelda A Okiro; Mwanajuma Ngama; Ann Bett; Patricia A Cane; Graham F Medley; D James Nokes
Journal:  Trop Med Int Health       Date:  2008-05-08       Impact factor: 2.622

View more
  8 in total

Review 1.  Respiratory syncytial virus-associated hospitalisation in children aged ≤5 years: a scoping review of literature from 2009 to 2021.

Authors:  Michael Noble; Rabia Ali Khan; Brodie Walker; Emma Bennett; Nick Gent
Journal:  ERJ Open Res       Date:  2022-05-30

2.  Age-specific incidence rates and risk factors for respiratory syncytial virus-associated lower respiratory tract illness in cohort children under 5 years old in the Philippines.

Authors:  Fumihiko Ueno; Raita Tamaki; Mayuko Saito; Michiko Okamoto; Mariko Saito-Obata; Taro Kamigaki; Akira Suzuki; Edelwisa Segubre-Mercado; Hananiah D Aloyon; Veronica Tallo; Socorro P Lupisan; Hitoshi Oshitani
Journal:  Influenza Other Respir Viruses       Date:  2019-03-19       Impact factor: 4.380

3.  Respiratory syncytial virus acute respiratory infection-associated hospitalizations in preterm Mexican infants: A cohort study.

Authors:  Daniela Benítez-Guerra; Cecilia Piña-Flores; Miguel Zamora-López; Francisco Escalante-Padrón; Victoria Lima-Rogel; Ana María González-Ortiz; Marcela Guevara-Tovar; Sofía Bernal-Silva; Beatriz Benito-Cruz; Fernanda Castillo-Martínez; Luz E Martínez-Rodríguez; Vianney Ramírez-Ojeda; Nallely Tello-Martínez; Rodrigo Lomelí-Valdez; Jack Salto-Quintana; Sandra Cadena-Mota; Daniel E Noyola
Journal:  Influenza Other Respir Viruses       Date:  2020-01-09       Impact factor: 4.380

Review 4.  Epidemiology and Seasonality of Childhood Respiratory Syncytial Virus Infections in the Tropics.

Authors:  Manika Suryadevara; Joseph B Domachowske
Journal:  Viruses       Date:  2021-04-16       Impact factor: 5.048

5.  Role of age and birth month in infants hospitalized with RSV-confirmed disease in the Valencia Region, Spain.

Authors:  Ainara Mira-Iglesias; Clarisse Demont; F Xavier López-Labrador; Beatriz Mengual-Chuliá; Javier García-Rubio; Mario Carballido-Fernández; Miguel Tortajada-Girbés; Juan Mollar-Maseres; Germán Schwarz-Chavarri; Joan Puig-Barberà; Javier Díez-Domingo
Journal:  Influenza Other Respir Viruses       Date:  2021-11-24       Impact factor: 4.380

6.  Incidence of lower respiratory tract infection and associated viruses in a birth cohort in the Philippines.

Authors:  Kanako Otani; Mayuko Saito; Michiko Okamoto; Raita Tamaki; Mariko Saito-Obata; Taro Kamigaki; Irene C Lirio; Edelwisa Segubre-Mercado; Veronica Tallo; Socorro Lupisan; Hitoshi Oshitani
Journal:  BMC Infect Dis       Date:  2022-03-30       Impact factor: 3.090

7.  Risk of Transmission and Viral Shedding From the Time of Infection for Respiratory Syncytial Virus in Households.

Authors:  Hirono Otomaru; Johanna Beulah T Sornillo; Taro Kamigaki; Samantha Louise P Bado; Michiko Okamoto; Mariko Saito-Obata; Marianette T Inobaya; Edelwisa Segubre-Mercado; Portia P Alday; Mayuko Saito; Veronica L Tallo; Beatriz P Quiambao; Hitoshi Oshitani; Alex R Cook
Journal:  Am J Epidemiol       Date:  2021-12-01       Impact factor: 4.897

Review 8.  Innate Immune Responses to Highly Pathogenic Coronaviruses and Other Significant Respiratory Viral Infections.

Authors:  Hanaa Ahmed-Hassan; Brianna Sisson; Rajni Kant Shukla; Yasasvi Wijewantha; Nicholas T Funderburg; Zihai Li; Don Hayes; Thorsten Demberg; Namal P M Liyanage
Journal:  Front Immunol       Date:  2020-08-18       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.